Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Objectives:
- To determine the maximum tolerated dose of oral topotecan when administered with Temodar
to patients with malignant glioma
- To characterize any toxicity associated with the combination oral topotecan and Temodar.
- To observe patients for clinical antitumor response when treated with oral topotecan and
Temodar.